Sanna Iivanainen , Antti Kurtti , Viktor Wichmann , Heidi Andersen , Antti Jekunen , Riitta Kaarteenaho , Tuula Vasankari , Jussi P. Koivunen
{"title":"智能手机应用与书面材料在肺癌低剂量计算机断层扫描(LDCT)筛查中的减烟和戒烟效果对比:II 期开放标签随机对照试验","authors":"Sanna Iivanainen , Antti Kurtti , Viktor Wichmann , Heidi Andersen , Antti Jekunen , Riitta Kaarteenaho , Tuula Vasankari , Jussi P. Koivunen","doi":"10.1016/j.lanepe.2024.100946","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Counseling, nicotine replacement, and other cessation medications have been proven effective in smoking cessation. The wide-scale adoption of smartphones and other mobile devices has opened new possibilities for scalable and personalized smoking cessation approaches. The study investigated whether a smartphone application would be more effective than written material for smoking cessation and reduction in smoking in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer (NCT05630950).</p></div><div><h3>Methods</h3><p>This randomized controlled trial enrolled 201 current smokers with marked smoking history (smoked ≥15 cigarettes/day for ≥25 years or smoked ≥10 cigarettes/day for ≥30 years). Participants were stratified by age and pack-years and randomized in 1:1 fashion to the developed smartphone application (experimental arm) or written material (standard of care). All the subjects underwent LDCT screening. Self-reported smoking cessation at three and six months were the primary endpoints of the study. The smoking-related secondary endpoints of the study were the percentage of individuals who had reduced the number of smoked cigarettes/d from the baseline.</p></div><div><h3>Findings</h3><p>Between Nov 18, 2022, and Apr 14, 2023, 201 patients were screened at Oulu University Hospital, Finland, of whom all were randomly assigned to smartphone application (n = 101) or written cessation material (n = 100); 200 were included in the full analysis set. Study arms were well-balanced for all the studied demographic factors. Subjects randomized to the smartphone application arm had significantly higher rates for self-reported smoking cessation at three (19.8 versus 7.1%; OR 3.175 CI 95% 1.276–7.899) and six months (18.8 versus 7.1%; OR 2.847 CI 95% 1.137–7.128). In the experimental arm, individuals with a frequent use of the application had a higher chance for smoking cessation at three (p < 0.001) and six months (p = 0.003).</p></div><div><h3>Interpretation</h3><p>The study showed that the developed smartphone application increases the likelihood for smoking cessation in individuals undergoing lung cancer LDCT screening.</p></div><div><h3>Funding</h3><p><span>AstraZeneca</span>, <span>Roche</span>, and <span>Cancer Foundation Finland</span>.</p></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":null,"pages":null},"PeriodicalIF":13.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666776224001133/pdfft?md5=4c08a2b3c146fe6349f5f49e2ecbbafd&pid=1-s2.0-S2666776224001133-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Smartphone application versus written material for smoking reduction and cessation in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer: a phase II open-label randomised controlled trial\",\"authors\":\"Sanna Iivanainen , Antti Kurtti , Viktor Wichmann , Heidi Andersen , Antti Jekunen , Riitta Kaarteenaho , Tuula Vasankari , Jussi P. Koivunen\",\"doi\":\"10.1016/j.lanepe.2024.100946\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Counseling, nicotine replacement, and other cessation medications have been proven effective in smoking cessation. The wide-scale adoption of smartphones and other mobile devices has opened new possibilities for scalable and personalized smoking cessation approaches. The study investigated whether a smartphone application would be more effective than written material for smoking cessation and reduction in smoking in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer (NCT05630950).</p></div><div><h3>Methods</h3><p>This randomized controlled trial enrolled 201 current smokers with marked smoking history (smoked ≥15 cigarettes/day for ≥25 years or smoked ≥10 cigarettes/day for ≥30 years). Participants were stratified by age and pack-years and randomized in 1:1 fashion to the developed smartphone application (experimental arm) or written material (standard of care). All the subjects underwent LDCT screening. Self-reported smoking cessation at three and six months were the primary endpoints of the study. The smoking-related secondary endpoints of the study were the percentage of individuals who had reduced the number of smoked cigarettes/d from the baseline.</p></div><div><h3>Findings</h3><p>Between Nov 18, 2022, and Apr 14, 2023, 201 patients were screened at Oulu University Hospital, Finland, of whom all were randomly assigned to smartphone application (n = 101) or written cessation material (n = 100); 200 were included in the full analysis set. Study arms were well-balanced for all the studied demographic factors. Subjects randomized to the smartphone application arm had significantly higher rates for self-reported smoking cessation at three (19.8 versus 7.1%; OR 3.175 CI 95% 1.276–7.899) and six months (18.8 versus 7.1%; OR 2.847 CI 95% 1.137–7.128). In the experimental arm, individuals with a frequent use of the application had a higher chance for smoking cessation at three (p < 0.001) and six months (p = 0.003).</p></div><div><h3>Interpretation</h3><p>The study showed that the developed smartphone application increases the likelihood for smoking cessation in individuals undergoing lung cancer LDCT screening.</p></div><div><h3>Funding</h3><p><span>AstraZeneca</span>, <span>Roche</span>, and <span>Cancer Foundation Finland</span>.</p></div>\",\"PeriodicalId\":53223,\"journal\":{\"name\":\"Lancet Regional Health-Europe\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":13.6000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666776224001133/pdfft?md5=4c08a2b3c146fe6349f5f49e2ecbbafd&pid=1-s2.0-S2666776224001133-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Regional Health-Europe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666776224001133\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Regional Health-Europe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666776224001133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
摘要
背景咨询、尼古丁替代品和其他戒烟药物已被证明对戒烟有效。智能手机和其他移动设备的广泛应用为可扩展的个性化戒烟方法提供了新的可能性。该研究调查了智能手机应用在接受低剂量计算机断层扫描(LDCT)肺癌筛查(NCT05630950)的人群中是否比书面材料更有效地戒烟和减少吸烟。受试者按年龄和吸烟包年进行分层,并以 1:1 的方式随机分配到开发的智能手机应用程序(实验组)或书面材料(标准护理组)。所有受试者都接受了 LDCT 筛查。研究的主要终点是受试者在三个月和六个月后自我报告的戒烟情况。研究结果2022年11月18日至2023年4月14日期间,芬兰奥卢大学医院对201名患者进行了筛查,并随机分配他们使用智能手机应用(101人)或书面戒烟材料(100人);其中200人被纳入完整的分析集。各研究臂在所有研究的人口统计学因素方面都非常均衡。随机加入智能手机应用组的受试者在三个月(19.8% 对 7.1%;OR 3.175 CI 95% 1.276-7.899)和六个月(18.8% 对 7.1%;OR 2.847 CI 95% 1.137-7.128)时的自我报告戒烟率明显更高。该研究表明,开发的智能手机应用提高了接受肺癌LDCT筛查者戒烟的可能性。
Smartphone application versus written material for smoking reduction and cessation in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer: a phase II open-label randomised controlled trial
Background
Counseling, nicotine replacement, and other cessation medications have been proven effective in smoking cessation. The wide-scale adoption of smartphones and other mobile devices has opened new possibilities for scalable and personalized smoking cessation approaches. The study investigated whether a smartphone application would be more effective than written material for smoking cessation and reduction in smoking in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer (NCT05630950).
Methods
This randomized controlled trial enrolled 201 current smokers with marked smoking history (smoked ≥15 cigarettes/day for ≥25 years or smoked ≥10 cigarettes/day for ≥30 years). Participants were stratified by age and pack-years and randomized in 1:1 fashion to the developed smartphone application (experimental arm) or written material (standard of care). All the subjects underwent LDCT screening. Self-reported smoking cessation at three and six months were the primary endpoints of the study. The smoking-related secondary endpoints of the study were the percentage of individuals who had reduced the number of smoked cigarettes/d from the baseline.
Findings
Between Nov 18, 2022, and Apr 14, 2023, 201 patients were screened at Oulu University Hospital, Finland, of whom all were randomly assigned to smartphone application (n = 101) or written cessation material (n = 100); 200 were included in the full analysis set. Study arms were well-balanced for all the studied demographic factors. Subjects randomized to the smartphone application arm had significantly higher rates for self-reported smoking cessation at three (19.8 versus 7.1%; OR 3.175 CI 95% 1.276–7.899) and six months (18.8 versus 7.1%; OR 2.847 CI 95% 1.137–7.128). In the experimental arm, individuals with a frequent use of the application had a higher chance for smoking cessation at three (p < 0.001) and six months (p = 0.003).
Interpretation
The study showed that the developed smartphone application increases the likelihood for smoking cessation in individuals undergoing lung cancer LDCT screening.
Funding
AstraZeneca, Roche, and Cancer Foundation Finland.
期刊介绍:
The Lancet Regional Health – Europe, a gold open access journal, is part of The Lancet's global effort to promote healthcare quality and accessibility worldwide. It focuses on advancing clinical practice and health policy in the European region to enhance health outcomes. The journal publishes high-quality original research advocating changes in clinical practice and health policy. It also includes reviews, commentaries, and opinion pieces on regional health topics, such as infection and disease prevention, healthy aging, and reducing health disparities.